CD177 belongs to the Ly-6 gene superfamily supporting our assumption that CD177+ neutrophils in bev-treated patients are comparable to Ly6G/C+ immune cells in xenografts32; this is also underlined by the fact that depletion of Ly6G+ neutrophils by an antibody could restore efficacy of anti-VEGF therapy which alone did not suffice to block tumour growth in a syngeneic mouse model. This evidence concerns the gene CD177 and neoplasm.